Masimo to Report First Quarter 2023 Financial Results After Market Close on Tuesday, May 9

Rhea-AI Summary

Masimo (NASDAQ: MASI) announced it will release its first quarter 2023 financial results after the market closes on May 9, 2023. A conference call to discuss the results will commence at 1:30 p.m. PT (4:30 p.m. ET), led by Joe Kiani, Chairman and CEO, and Micah Young, CFO. Investors can register for the call to obtain the dial-in details. The company specializes in innovative medical technology and monitoring solutions, boasting the industry-leading Masimo SET® pulse oximetry system. With over 200 million patients monitored globally, it is highly regarded in health care. However, certain products, including ORi and RPVi, have not received FDA clearance in the U.S. More about Masimo.

Positive

• Masimo SET® pulse oximetry has been shown in over 100 studies to outperform competing technologies.
• The company is a key player in monitoring solutions with an estimated 200 million patients monitored worldwide.

Negative

• ORi, RPVi, and Radius VSM have not received FDA 510(k) clearance and are not available for sale in the United States.

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)

IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) will release first quarter 2023 financial results for the period ended April 1, 2023, after the market closes on Tuesday, May 9, 2023. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer.

To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered participants via email.

Conference Call Registration Link (Please register to obtain the dial-in number):

https://conferencingportals.com/event/nUSpRIEm

A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the Company’s website.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET^® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET^® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. Masimo SET^® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world, and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll. In 2005, Masimo introduced rainbow^® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb^®), oxygen content (SpOC™), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), Pleth Variability Index (PVi^®), RPVi™ (rainbow^® PVi), and Oxygen Reserve Index (ORi^™). In 2013, Masimo introduced the Root^® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine^® Brain Function Monitoring, O3^® Regional Oximetry, and ISA™ Capnography with NomoLine^® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters^® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7^®, Radius PPG^®, and Radius VSM™, portable devices like Rad-67^®, fingertip pulse oximeters like MightySat^® Rx, and devices available for use both in the hospital and at home, such as Rad-97^®. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris^® Gateway, iSirona™, Patient SafetyNet, Replica^®, Halo ION^®, UniView^®, UniView :60™, and Masimo SafetyNet^®. Its growing portfolio of health and wellness solutions includes Radius T°^® and the Masimo W1™ watch. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature.

ORi, RPVi, and Radius VSM have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005421/en/

Investor Contact:

Eli Kammerman

(949) 297-7077

ekammerman@masimo.com

Media Contact:

Evan Lamb

(949) 297-3376

elamb@masimo.com

Source: Masimo

FAQ

When will Masimo release its first quarter 2023 financial results?

Masimo will release its first quarter 2023 financial results after the market closes on May 9, 2023.

What time is the Masimo conference call regarding the financial results?

The Masimo conference call to discuss the financial results will begin at 1:30 p.m. PT (4:30 p.m. ET) on May 9, 2023.

What is Masimo's primary product for patient monitoring?

Masimo's primary product for patient monitoring is the Masimo SET® pulse oximetry system.

How many patients have been monitored with Masimo technologies?

Masimo technologies have monitored over 200 million patients globally.

Are any Masimo products not available in the U.S.?

Yes, products such as ORi, RPVi, and Radius VSM have not received FDA 510(k) clearance and are not available for sale in the United States.